Nutraceuticals (i.e., complementary and alternative medicines) are gaining ground as therapeutic modalities for inflammatory and autoimmune disorders, primarily due to their low toxicity and high patient compliance. Several species of Hypericum have been shown to possess immunomodulatory capabilities in many disease models. However, the therapeutic potential of the chemically unique Hypericum gentianoides (HG) is largely untested. We investigated the efficacy of an orally administered ethanolic extract of HG (HGEE) to prophylactically inhibit/ameliorate the spontaneous colitis that develops in mdr1a deficient (mdr1a -/-) mice.
macroscopic or microscopic effects observed following the daily administration of HGEE to wild type FVB mice. Histological evaluation of colonic tissue revealed a decrease in neutrophil infiltration in HGEE treated mdr1a -/-mice, which was substantiated by a significant decrease (p synergy between chemical compounds [18, 19] . Recently it was demonstrated that an ethanolic extract of Prunella vulgaris attenuated the severity of spontaneous colitis in mdr1a -/-mice [20] .
It has been recognized that consumption of selected species of Hypericum or their extracts could be therapeutically or prophylactically efficacious in the treatment of IBD due to their use in treating gastrointestinal illness, as well as reported anti-inflammatory, analgesic, wound healing, and free radical inhibitory effects [21] [22] [23] [24] [25] . The chemical constituents of the most commonly known species of this genus, Hypericum perforatum (common name, St. John's Wort), are well defined and include several flavonoids: quercetin, hyperoside, isoquercitrin, quercitrin, rutin, and amentoflavone [26, 27] . Of these compounds, rutin has been shown to ameliorate experimental colitis [28] . H. perforatum has been demonstrated to attenuate TNBSinduced colitis in rats [29] . H. perforatum contains the phenols caffeic acid and chlorogenic acid, in addition to tannins. Caffeic acid has been shown to modulate the IL-12/IL-23 pathway, while proanthocyanidins inhibit NFκB activity [30, 31] . The bioactive compounds that have received the most attention in H. perforatum are the photoactive compounds hypericin and pseudohypericin, as well as hyperforin [32] . While the biological activity, including antiinflammatory activity, of these three components have been evaluated, they can also cause photosensitivity and toxicity in animals and humans making H. perforatum less attractive as a medicinal plant [33] [34] [35] .
While the species H. gentianoides (HG) is dispersed throughout the eastern United States, their biochemical and medicinal properties are not well documented. However, it is known that HG has been used by Native Americans to reduce gastrointestinal illness and fever and to speed wound healing. This leaves one to speculate the ability of HG to have beneficial effects with respect to ameliorating mucosal inflammation associated with IBD [36] . Compared to other species of Hypericum, the chemical composition of HG is unique in that it contains the antibacterial compounds uliginosin A and B, but lacks hypericin, pseudohypericin, and hyperforin [37, 38] . This suggests that HG extracts would have fewer toxic side effects when compared to other Hypericum species. It was previously shown that an extract of HG reduced prostaglandin E2 production by stimulated RAW 264.7 macrophage cells with no significant cytotoxicity [39] . Neither HG nor any extracts of HG have been evaluated for biologic activity in vivo. In this study, we evaluate the anti-inflammatory and immunomodulatory activities of HG ethanolic extract (HGEE) in the mdr1a
-/-mouse model of spontaneous colitis. Based on the recently reported chemical composition of HG [37, 38] , the ability to reduce inflammatory prostaglandin synthesis and the anti-inflammatory activity, it was hypothesized that HGEE will reduce the severity of mucosal inflammation associated with the onset of spontaneous colitis. The results of this study demonstrate that the daily administration of HGEE ameliorated the severity of colitis that naturally develops in mdr1a -/-mice. [27] . Upon complete drying of the extract by evaporation, the weight of the extracted material was recorded; the residue was lyophilized and stored at -20°C until solubilized in a final working solution of 5% EtOH (the lowest concentration of EtOH that would allow solubilization) at a final plant extract concentration of 24 mg/mL. As previously described, the dose of HGEE used in these studies was based upon the dose of Hypericum perforatum (i.e., St. John's Wort) used in humans and adjusted 10-fold to be metabolically equivalent for use in mice [40] . The working HGEE was divided into 2 mL aliquots and stored at -20°C until use. HG extracts from NCRPIS were screened for endotoxin by using the Limulus Amebocyte Lysate Test (BioWhittaker, Inc., Walkersville, MD) according to manufacturers' specifications, and there was no detectable endotoxin present in the extract (data not shown). EtOH vehicle alone. N = 4 to 10 mice per group per experiment. Gavage was performed using a 20 gauge feeding needle once a day beginning at 6 weeks of age until the mice reached twenty weeks of age, or were removed from the study because of weight loss exceeding 15 % of their peak body weight. At necropsy, mice were euthanized by CO 2 asphyxiation. Following euthanasia, blood was collected by cardiac puncture and sections of ceca and proximal colon were excised, washed, and stored for further histological and MPO enzymatic analysis. Serum was analyzed by multiplex assay to measure cytokine and chemokine levels.
METHODS

Hypericum gentianoides extract preparation
Animals
Macroscopic typhlocolitis assessment
Following euthanization, the colon and cecum were excised, photographed, colon length was measured, and macroscopically scored for lesions severity. Gross typhlocolitic lesions were scored using a nine-point additive scale: a score of zero being a healthy colon and a score of 9 being a maximally diseased colon. Score parameters evaluated included: 1) cecal atrophy, 2) presence of an enlarged cecal tonsil or other enlarged lymphoid aggregates, 3) cecal emptying, 4) watery or mucoid intraluminal cecal and/or colonic contents, 5) bloody cecal contents, 6) bloody colonic contents, 7) visible thickening and rigidity of the cecum, 8) visible thickening and rigidity of the colon, and 9) absence of formed fecal pellets in the colon.
Histopathological assessment
Sections of excised cecum and proximal colon were placed in 10% buffered formalin, paraffin embedded, sectioned, and routinely stained with hematoxylin and eosin. Stained colonic and cecal sections were blindly scored by a board certified pathologist (Dr. Jesse Hostetter, Iowa State University, Ames, IA) as previously described [20, 41, 42] . Microscopic mucosal lesion scores were based on five separate parameters, with each parameter scored on a scale of 0 to 5 (5 = maximum severity). Score parameters include: 1) ulceration of the mucosa; 2) extent of inflammatory cell infiltrate; 3) mucosal edema characterized by the extent of lymphatic and vascular distortion from the normal architecture; 4) stromal collapse and necrosis of the glands; 5) glandular hyperplasia characterized by the distribution of enterocytes along the base of the gland; and additionally mucosal height (measured by optical micrometer) was added to generate additive tissue score. Additionally, the character of the inflammatory infiltrate was also recorded.
Myeloperoxidase assay
Myeloperoxidase (MPO) activity was used as a measure of neutrophil/granulocyte accumulation in proximal colonic and cecal tissues. The MPO assay was performed as previously described [20, 43] . Briefly, proximal colon and cecal sections were collected at necropsy and FVB WT mouse serum was used for a positive control. Tissue was trimmed to approximately 35 mg, homogenized, and then the recovered cells were enumerated. Afterwards, the cells were sonicated, cellular debris was removed by centrifugation, and the supernatant fluid was collected and analyzed for total protein. Individual lysates were analyzed in triplicate by adding 3,3`,5,5`-tetramethylbenzidine dihydrochloride hydrate, followed immediately hydrogen peroxide (5 mM). After two minutes, sulfuric acid was added to stop the reaction and the optical density was measured at 405 nm using SOFTmax PRO 4.0 (V-Max, Molecular Devices, USA). The MPO content was determined by comparison to the standard curve and MPO activity was expressed as the relative units of enzyme activity per gram of wet weight of tissue.
Serum cytokine quantification
Following euthanization of mdr1a -/-and FVB WT mice, blood was collected via cardiac puncture.
The blood was allowed to clot for 24 hours at 4 °C after which samples were centrifuged at 10,000 x g for 10 minutes. Serum was then removed and stored at -20 °C until use. The day of assay, serum samples were thawed to room temperature. Concentrations of cytokines and chemokines of interest were measured using the Milliplex mouse cytokine-chemokine 32-plex multiplexed flow-cytometric assay kit (EMD Millipore, Billerica, MA). Analytes screened include: Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, CXCL10, KC, LIF, LIX, M-CSF, MCP-1, CXCL9, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, VEGF. The assay was performed according to the manufacturer's instructions. Individual serum samples were diluted 1:1 in supplied assay buffer. The pre-conjugated multiplex analyte beads were added to each well and the samples were incubated at 4 °C overnight on a plate shaker (Barnstead International Titer Plate Shaker, setting #5, Model #4625). Following vacuum filtration and washing, the detection antibody was added to all the wells and the plate was incubated at room temperature while shaking for two hours. The streptavidin-phycoerythrin was then added to each well and incubated for 30 minutes at room temperature while shaking. After a final vacuum filtration and rinse, the beads were resuspended in sheath fluid and the mean fluorescence intensity was measured using Luminex platform technology (The FlowMetric System, Luminex, Austin, TX). Mean fluorescence intensity values were subsequently converted to concentrations using a 5-parameter logistic or line curve-fitting method in MasterPlex QT Software (MiraiBio Group, San Francisco, CA).
Statistical analysis
All data, except survival curves, were evaluated by the Kruskal-Wallis test with Dunn's multiple comparisons test. Statistically non-significant differences in the mdr1a -/-groups were further evaluated by the Mann-Whitney test for ordinal data and unpaired t-test with Welch's correction for continuous data. Survival curves were evaluated by the Log-rank (Mantel-Cox) test. A pvalue of < 0.05 was considered statistically significant. Prism 6 was used for all statistical calculations.
RESULTS AND DISCUSSION
The ethanolic extract of Hypericum gentianoides delays the onset of severe colitis and decreases the severity of macroscopic disease in mdr1a -/-mice.
Previously published data demonstrates that mdr1a -/-mice spontaneously develop colitis between 8 and 36 weeks of age, with the average age of disease onset being 20 weeks [44] . Wilk and colleagues have demonstrated that the expression of proinflammatory cytokines is upregulated as early as two weeks of age in mdr1a -/-mice [45] . Mice that are deficient in mdr1a are also genetically more susceptible to barrier disruption resulting in the increased exposure of the lamina propria to phlogistic components present in the lumen of the gut [44, 45] . The mdr1a
-/-mouse model is characterized by an increase in colonic inflammation that begins to develop by 8 weeks of age [44] . The inflammation becomes transmural, multifocal, and is characterized by the production of multiple inflammatory cytokines and chemokines [46, 47] . The underlying mechanism associated with the onset of colitis in this model as well as the genetic basis for the onset of colitis are consistent with some forms of human IBD, adding to the relevance of this model in screening CAM products (e.g., botanical extracts) as potential therapeutic or prophylactic modalities for IBD [48, 49] . The current study is novel due to its evaluation of the in vivo medicinal benefits of orally administering an extract derived from Hypericum gentianoides in the context of a spontaneous model of murine colitis. Using the mdr1a -/-model of spontaneous murine colitis, we evaluated the anti-inflammatory efficacy of oral HGEE in comparison to vehicle (5% ethanol in PBS) alone. As shown in Figure 1 , the timeframe and severity of colitis in vehicle-treated mdr1a -/-mice was consistent with that reported in previous studies [44, 45] . As expected, FVB WT mice treated with either the HGEE or the vehicle alone remained free of colitis (data not shown). As a positive control, a separate group of mdr1a -/-mice was treated with metronidazole in there drinking water. As expected, the metronidazole treatment significantly (p ≤ 0.05) reduced the onset of clinical disease ( Figure 1 ) and the development of microscopic inflammation (data not shown). Only two metronidazole-treated mdr1a -/-mice developed clinical signs of disease, albeit mild, underscoring the importance of the resident microbiota in the pathogenesis of colitis that develops in the mdr1a -/-mice [44] .
To determine the effectiveness of HGEE as a treatment for spontaneous colitis, six-week old mdr1a -/-mice were gauaged once daily with vehicle or 4.8 mg HGEE. As anticipated, the majority of vehicle treated mdr1a -/-mice (11 out of 16, 68.8 %) developed severe colitis prior to 20 weeks of age. In contrast, only 6 of the 16 (i.e., 37.5%) HGEE treated mice developed clinical signs of colitis (i.e., ≥ 15% weight loss) prior to reaching 20 weeks of age such that they were removed from the study (Figure 1 -/-mice remaining on study over time. Mdr1a -/-mice were removed from the study as they developed significant clinical signs of disease (i.e., ≥ 15 % loss of body weight) or at 20 weeks of age (i.e., the termination of the experiment) as described in methods. a p < 0.05, b p < 0.01 as compared to vehicle treated mdr1a -/-mice using a nonparametric analysis with a Kruskal-Wallis post hoc test. This adapted survival curve is representative of two separate experiments (vehicle n = 16, metronidazole n = 10, HGEE n = 16).
While the HGEE treated mdr1a -/-mice had a better clinical outcome than vehicle treated mdr1a -/-mice, it was essential to evaluate the gastrointestinal tract for severity of marcoscopic and microscopic lesions. Representative photographs of ceca and colons (Figure 2) show the extent of macroscopic tissue changes that developed in vehicle treated mdr1a -/-mice. In these mice, it was readily apparent that the ceca were atrophied with visible, prominent cecal tonsils suggestive of local immune activation and inflammation. It was also noted that there was a decrease in the amount of cecal and colonic contents and that both cecal and colonic tissues were notably thickened. In the mdr1a -/-mice, blood was often observed in cecal and colonic contents and formed fecal pellets were absent. Conversely, the ceca and colons of HGEE treated mdr1a Macroscopically, severe typhlocolitis (a score ≥ 5) was observed in 75 % of vehicle treated mdr1a -/-mice compared to only 25 % of HGEE treated mdr1a -/-mice ( Figure 3A ). All vehicle treated mdr1a -/-mice displayed at least mild macroscopic disease, while all of the macroscopic scores for HGEE treated mdr1a -/-mice are below the median score of the vehicle treated mdr1a -/-mice ( Figure 3A) . HGEE treatment significantly (p < 0.01) attenuated the severity of macroscopic disease when compared to vehicle treatment in mdr1a -/-mice. While not statistically significant, there was a trend that colon lengths in HGEE treated mdr1a -/-mice were less affected when compared to vehicle treatment ( Figure 3B ) which supports the significant differences noted for the overall macroscopic scores. ( Figure 3A ). As expected, no FVB WT mice exhibited any clinical signs of disease or any microscopic lesions regardless of the administration of HGEE or not ( Figure 3, A and B) . 
Impact of H. gentianoides treatment on the severity of histopathological lesions
Histological inflammation of cecal and colonic tissues was scored based on changes in mucosal height, ulceration, extent and character of inflammatory cell infiltrate, edema, stromal collapse and glandular necrosis, and glandular hyperplasia (Tables 1 and 2 ). Both the colons and ceca of vehicle treated mdr1a -/-mice were characterized by crypt hyperplasia, extensive transmural ulceration and inflammatory infiltrate, as well as occasional submucosal edema and stromal collapse (Table 1 and Figure 4) . HGEE treated mdr1a -/-mice exhibited significant (p < 0.05) improvement in colonic neutrophil infiltration (Table 1) , cecal ulceration, stromal collapse, and an overall lower cecal score related to the severity of mucosal inflammation ( Table 2) -/-mice, it is not surprising that the HGEE treatment did not prevent the onset of colitis; however, HGEE treatment did significantly ameliorate macroscopic and microscopic lesions in mdr1a -/-mice when compared to vehicle treated mdr1a -/-mice. While longer studies would be required, these results suggest that oral administration of HGEE could be used to reduce the morbidity (i.e., improved Disease Activity Index) of these treated mice.
The absence of clinical disease in HGEE treated mdr1a -/-mice correlated with the presence of mild to moderate microscopic cecal ulceration and mucosal necrosis, as well as an overall lower histopathological score in these mice (Figure 4 , Tables 1 and 2 ). These lower (i.e., attenuated) microscopic and macroscopic disease scores observed in the HGEE treated mdr1a
-/-mice could be attributed to the significant reduction in the neutrophilic infiltration into the cecal and colonic mucosa of these mice (a 25% and 31% improvement, respectively). MPO activity, a known contributor to and marker of inflammation, was similarly reduced in the colons and ceca of HGEE treated mdr1a -/-mice [50] [51] [52] . Tissue damage due to excessive neutrophil infiltration and activation is known to contribute to disease severity in IBD [53] [54] [55] [56] [57] . A greater number of microscopic parameters were improved in the ceca of HGEE treated mdr1a -/-mice. However, the reduction in neutrophil infiltrate and subsequent MPO activity was less dramatic in the cecal tissues than in the colons of these mice. This may indicate that the recruitment and accumulation of neutrophils played an important role in the severity of lesion development but was not the only inflammatory parameter affected by HGEE that contributed to the amelioration of colitis in these treated mdr1a -/-mice.
The trend for increased presence of plasma cells observed histologically in the colons and ceca of HGEE treated mdr1a -/-mice was unexpected. It has been previously documented that increasing numbers of plasma cells are found in the tissues of diseased mdr1a -/-mice [58] . Given that HGEE treated mdr1a -/-mice exhibited significantly less severe colitic disease, it is unclear what caused the increase in plasma cells in the cecal and colonic tissues of these mice nor what the role of these plasma cells would be in the attenuation of lesion severity. In the absence of inflammation, HGEE treatment did not increase the numbers of plasma cells in the mucosa of FVB WT mice indicating that there is no direct cause or effect related to the HGEE treatment and the increase in mucosal plasma cells. 15.9 ± 0.9 13.8 ± the time of necropsy were formalin fixed, paraffin embedded and subject to routine hematoxylin and eosin staining. Photographs were chosen based on the average macroscopic and microscopic score data for each group and are representative of two independent experiments (see Figure 2 for number of animals in each treatment group).
As a measure of inflammation and infiltration of granulocytes into the mucosal tissue, MPO activity was measured in colonic and cecal homogenates ( Figure 5 ). In comparison to tissue samples from the vehicle-treated mdr1a -/-mice, the associated MPO enzymatic activity was significantly diminished in colons of HGEE treated mdr1a -/-mice (p < 0.05) ( Figure 5A ). In addition, cecal tissue of HGEE treated mdr1a -/-mice presented with less MPO activity consistent with the less severe histologically scores and less prominent neutrophilic infiltration ( Figure 5B ).
Figure 5
Metronidazole and HGEE reduce local myeloperoxidase (MPO) activity in the colons (A) and ceca (B) of mdr1a-/-mice. Homogenates of colonic or cecal tissue were used to assay for MPO activity. a p < 0.05, b p < 0.01 as compared to mdr1a -/-vehicle with a Kruskal-Wallis test.
Data is representative of: FVB WT vehicle n = 6, mdr1a -/-vehicle n = 10, HGEE n = 10.
Together, these data suggest that the ability of orally administered HGEE to reduce neutrophil infiltration and increase lamina proprial plasma cells in the ceca and colons correlated with less severe inflammation and tissue injury that is characteristically associated with the spontaneous colitis that develops in untreated mdr1a -/-mice.
Impact of the ethanolic extract of H. gentianoides on the induction of chemotactic and proinflammatory cytokines
To further investigate inflammatory modulation related to improved macroscopic and microscopic cecal and colonic health, serum samples collected at necropsy were examined for the presence of cytokines and chemokines. Many analytes including G-CSF, IL-6, CXCL10, KC, CXCL9, and TNFα were significantly (p < 0.01) elevated in vehicle-treated mdr1a -/-mice compared to FVB WT controls (Table 3) . G-CSF, KC, and TNFα were significantly (p < 0.05) lower in HGEE treated mdr1a -/-mice (Table 3) . It is clear from these data that the production of chemokines and inflammatory cytokines were reduced in HGEE treated mdr1a -/-mice. Analysis of the levels of serum cytokine from HGEE treated mdr1a -/-mice further supports the anti-inflammatory potential of this botanical extract. HGEE treatment of mdr1a -/-mice resulted in a significant reduction in the detection of G-CSF, KC, and TNFα. G-CSF and KC are both stimulatory and chemoattractant for neutrophils [59, 60] . Their downregulation by HGEE treatment is consistent with the decrease in colonic and cecal neutrophil infiltrate seen in HGEE treated mdr1a -/-mice. HGEE reduction of TNFα serum concentrations is a compelling observation, as TNFα has been directly implicated in the pathogenesis and chronicity of IBD [61] . TNFα has previously been shown to be elevated in untreated mdr1a -/-mice [47] . There was a trend for the presence of increased levels of IL-6 in the sreum of HGEE treated mdr1a -/-mice.
Depending on the cytokine milieu of the mucosal microenvironment, it should be noted that IL-6 can be either pro-inflammatory or anti-inflammatory by enhancing T helper 17 cell development or regulatory T cell development, respectively [62] . The potential benefits of elevated IL-6 is supported by a recent study which reported that IL-6 levels are elevated in the tissues of human patients with active IBD in the absence of microscopic and macroscopic inflammation suggesting active immune regulation even in the absence of demonstrable inflammation [63] . The observed reduction in the levels of cytokine/chemokines noted in the present study is consistent with the amelioration of microscopic and macroscopic lesions and can be related to the associated reduction in granulocyte and neutrophil activity in HGEE treated mdr1a -/-mice.
CONCLUSIONS
In summary, the ethanolic extract of Hypericum gentianoides was shown to possess antiinflammatory and immunomodulatory potential based on its ability to attenuate inflammation in mdr1a-/-mice that develop spontaneous colitis. This activity is likely related to the flavonoid and polyphenolic compounds in the extract. Our work highlights the need for further study (e.g., increased doses per day) of HGEE, the potential synergy of its active components, and its efficacy in other inflammatory disease models. Because of the spontaneous (i.e., genetic) nature of this model, it better represents human IBD than chemically-induced models of colitis and provides a basis for evaluating the medicinal benefits of CAM products.
